Compound 60 has an incredibly higher affinity to MDM2 (Ki < one nM), strong mobile action, and a very good oral pharmacokinetic profile. Compound sixty is capable of attaining complete and extended-Long lasting tumor regression in vivo and it is at this time in phase I clinical trials for cancer https://dantesydjm.tusblogos.com/31760795/the-smart-trick-of-ro-5126766-that-nobody-is-discussing